Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma

Exclusion Criteria

• •Previous treatment with an anti PD-1, anti PD-L1, anti PD-L2, anti-CD137, or anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
• •Previous GDP therapy
• •Previous serious hypersensitivity reaction or symptomatic pancreatitis from L-asparaginase
• •Uncontrolled central nervous (CNS) disease
• •Uncontrolled hepatitis B or C
• •Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
• •All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue must have resolved to grade 1 (NCI CTCAE version 4) or baseline before administration of study drug
• •Subjects with \> grade 1 peripheral neuropathy
• •Any serious or uncontrolled medical disorder, autoimmune disorder or active infection that, in the opinion of the investigator, may increase the risk associated with study participation, study drug administration or would impair the ability fo the subject to receive the study drug
• •Subjects who have had prior malignancies (other than NKTL) for ≤5 year with exception of currently treated basal cell, squamous cell carcinoma of the skin or carcinoma "in situ" of the cervix or breast.
• •Subjects who have had other anti-cancer therapy including radiation or experimental drug therapy within 28 days of enrollment
• •Subjects with known allergies or hypersensitivities to the study drugs
• •Prisoners or subjects who are involuntarily incarcerated
• •Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness
• •Pregnant women or women who are breastfeeding are excluded from this study
• •Inclusion of women and minorities:
• •Men and women of all ethnic groups are eligible for this study